- Home
- IREN vs MIRM Comparison
IREN vs MIRM Comparison
Compare IREN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IREN
- MIRM
- Stock Information
- Founded
- IREN 2018
- MIRM 2018
- Country
- IREN Australia
- MIRM United States
- Employees
- IREN N/A
- MIRM N/A
- Industry
- IREN EDP Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- IREN Technology
- MIRM Health Care
- Exchange
- IREN Nasdaq
- MIRM Nasdaq
- Market Cap
- IREN 2.5B
- MIRM 2.5B
- IPO Year
- IREN 2021
- MIRM 2019
- Fundamental
- Price
- IREN $18.99
- MIRM $53.05
- Analyst Decision
- IREN Strong Buy
- MIRM Strong Buy
- Analyst Count
- IREN 10
- MIRM 9
- Target Price
- IREN $19.22
- MIRM $66.22
- AVG Volume (30 Days)
- IREN 32.7M
- MIRM 423.5K
- Earning Date
- IREN 08-27-2025
- MIRM 08-06-2025
- Dividend Yield
- IREN N/A
- MIRM N/A
- EPS Growth
- IREN N/A
- MIRM N/A
- EPS
- IREN N/A
- MIRM N/A
- Revenue
- IREN $377,821,000.00
- MIRM $379,251,000.00
- Revenue This Year
- IREN $168.58
- MIRM $35.83
- Revenue Next Year
- IREN $79.94
- MIRM $16.83
- P/E Ratio
- IREN N/A
- MIRM N/A
- Revenue Growth
- IREN 128.24
- MIRM 69.31
- 52 Week Low
- IREN $5.13
- MIRM $36.20
- 52 Week High
- IREN $21.54
- MIRM $54.78
- Technical
- Relative Strength Index (RSI)
- IREN 81.39
- MIRM 61.93
- Support Level
- IREN $17.49
- MIRM $50.96
- Resistance Level
- IREN $21.54
- MIRM $53.59
- Average True Range (ATR)
- IREN 1.69
- MIRM 1.61
- MACD
- IREN 0.01
- MIRM -0.13
- Stochastic Oscillator
- IREN 59.91
- MIRM 70.02
About IREN Iris Energy Limited
IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.